The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase
Authors:
- Craig D.C. BaileyCBCraig D.C. Bailey
- Gail V.W. JohnsonGJGail V.W. Johnson
- 1 June 2006
- journal article
- research article
- Published by Elsevier in Neurobiology of Aging
- Vol. 27 (6) , 871-879
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal deathNature, 2004
- Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseasesMolecular and Cellular Neuroscience, 2004
- Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeatsJournal of Neurochemistry, 2004
- Transglutaminases: crosslinking enzymes with pleiotropic functionsNature Reviews Molecular Cell Biology, 2003
- Inhibiting Caspase Cleavage of Huntingtin Reduces Toxicity and Aggregate Formation in Neuronal and Nonneuronal CellsJournal of Biological Chemistry, 2000
- Differential Expression of Multiple Transglutaminases in Human BrainJournal of Biological Chemistry, 1999
- Polyglutamine Domains Are Substrates of Tissue Transglutaminase: Does Transglutaminase Play a Role in Expanded CAG/Poly‐Q Neurodegenerative Diseases?Journal of Neurochemistry, 1997
- Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic MiceCell, 1996
- GTP hydrolysis by guinea pig liver transglutaminaseBiochemical and Biophysical Research Communications, 1989
- Enzymic basis for the Ca2+ion-induced crosslinking of membrane proteins in intact human erythrocytesBiochemistry, 1978